Last reviewed · How we verify
low-dose dopamine + low-dose furosemide
Low-dose dopamine stimulates renal dopamine receptors to promote natriuresis and renal blood flow, while low-dose furosemide enhances diuresis, together improving renal perfusion and urine output in acute kidney injury or cardiorenal syndrome.
Low-dose dopamine stimulates renal dopamine receptors to promote natriuresis and renal blood flow, while low-dose furosemide enhances diuresis, together improving renal perfusion and urine output in acute kidney injury or cardiorenal syndrome. Used for Acute kidney injury with oliguria, Cardiorenal syndrome, Acute decompensated heart failure with renal dysfunction.
At a glance
| Generic name | low-dose dopamine + low-dose furosemide |
|---|---|
| Sponsor | Larissa University Hospital |
| Drug class | Combination diuretic and inotropic agent |
| Target | Dopamine-1 (DA1) receptor; Na-K-2Cl cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Nephrology |
| Phase | FDA-approved |
Mechanism of action
Dopamine at low doses (1–3 mcg/kg/min) activates dopamine-1 (DA1) receptors on renal vasculature and tubules, causing vasodilation and increased glomerular filtration without systemic vasoconstriction. Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb, promoting sodium and water excretion. The combination is designed to synergistically improve renal function by enhancing both renal perfusion (dopamine) and diuretic response (furosemide) while minimizing systemic hemodynamic compromise.
Approved indications
- Acute kidney injury with oliguria
- Cardiorenal syndrome
- Acute decompensated heart failure with renal dysfunction
Common side effects
- Hypotension
- Tachycardia
- Hypokalemia
- Hyperglycemia
- Arrhythmias
Key clinical trials
- REWORD-HF REverse WOrsening Renal Function in Decompensated Heart Failure (PHASE4)
- Dopamine in Acute Decompensated Heart Failure II (PHASE4)
- Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: